Fairfax, VA (PRWEB) September 04, 2013
In their latest Special Report, PharmSouce experts present an important expert analysis of the bio/pharmaceutical contract dose manufacturing industry. Founded on the industry’s most comprehensive database of the dose CMO industry (PharmSource’s STRATEGIC ADVANTAGE Database of Contract Service Providers), this analysis is driven by the organization's proprietary model of the dose manufacturing industry which is continuously updated and refined. The model and assumptions are fully explained so readers can understand how the analysis and conclusions were established.
The report characterizes the bio/pharmaceutical contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability, and provides PharmSource’s expert outlook for the industry.
For purposes of this report, the contract dose manufacturing universe includes companies that actively promote themselves as contract manufacturers (CMOs) and produce client formulations for pharmaceuticals supplied to the highly regulated markets in North America, Europe and Japan. The contract dose manufacturing universe is defined by 195 companies headquartered primarily in North America, Europe, Japan and India.
This 27-page report includes an Executive Summary, and chapters on Industry Composition and Size, CMO Market Shares, and CMO Profitability, and concludes with a chapter on What it Means, which further assesses the implications of the conclusions for the dose CMO industry. In addition, appendices on methodology and a listing of companies included in the CMO universe as defined are included.
Who should read and study this
Copyright©2012 Vocus, Inc.
All rights reserved